Carey Danis & Lowe | Attorneys at Law
  • Home
  • Our Attorneys
    • About Carey Danis & Lowe
  • Featured Cases
  • Practice Areas
    • Antitrust
    • Class Actions
      • AT&T Cell Phone Bill Cramming
      • AT&T Telephone Bill Cramming
      • Credit Card Payment Protection
    • Defective & Faulty Medical Device Litigation
      • Guidant Defibrillator
      • Hip & Knee Replacement
      • Ob Tape & Slings
      • Transvaginal Mesh
    • Medical Malpractice
    • Personal Injury
      • Truck & Car Accidents
    • Pharmaceutical Litigation
      • Accutane®
      • Actos®
      • Asbestos Mesothelioma
      • Avandia®
      • Celexa®
      • Levaquin®
      • Lexapro®
      • Luvox®
      • Mirena®
      • NuvaRing®
      • Paxil®
      • Pradaxa®
      • Prozac®
      • Symbyax®
      • Topamax®
      • Wellbutrin®
      • Yaz® Yasmin®
      • Zoloft®
    • Product Liability
    • Securities Fraud
    • Unfair & Deceptive Trades
  • Firm News
    • Firm Resume
    • Press Release
    • Testimonials
  • Contact Us
    • via Email
    • via Facebook
    • via LinkedIn
    • via Twitter
    • via RSS
  • Blog
Like Carey Danis & Lowe on FacebookConnect With Carey Danis & Lowe on LinkedInFollow Carey Danis & Lowe on TwitterSubscribe to Carey Danis & Lowe via RSS

  P.  800.721.2519
 Ask a Nurse

Home » Defective Medical Device litigation • Hip/Knee Replacement » FDA Panel Concludes There Is N ...

FDA Panel Concludes There Is No Reason to Use Metal-on-Metal Hip Replacements

On June 28, 2012 the Federal Drug Administration discussed metal-on-metal (MoM) hip systems and highlighted issues relating to local and systemic complications.  Health experts concluded there is little reason for the continued use of these devices due to growing evidence that they expose patients to dangerous metallic particles.

For many decades physicians preferred orthopedic implants which are coated with plastic or ceramic.  In the past ten years, a growing movement towards metal devices occurred after laboratory tests suggested these devices would experience less wear and tear.  The metal-on-metal devices also were thought to dislocate less frequently.   In 2010 approximately one third of hip implant procedures utilized metal-on-metal implants with many patients unaware of the increased risks including metal toxicity. It is estimated that more than half-million U.S. patients currently have metal hip replacements.

Recent data suggests that as the metal-on-metal devices wear, they can release metallic particles which in turn cause tissue and muscle damage. British experts in March of 2012 found evidence that metal-on-metal implants are four times more likely to fail compared to plastic and ceramic models.  Dr. William Rohr of Mendocino Coast Disctrict Hospital and chair of the panel notes, “I do not use metal-on-metal hips, and I can see no reason to do so.”  Many doctors are now returning to the plastic and ceramic models which were once the standard of care.

FDA experts suggested that patients with pain and other symptoms who have metal-on-metal devices should get x-rays and blood tests to monitor metal levels.  For those without pain, an annual x-ray is sufficient monitoring according to the panel.

In 2010, DuPuy Orthopaedics, a subsidiary of Johnson & Johnson declared a recall of the ASR hip replacement system.   Many patients who had already had the defective device implanted have filed lawsuits against DuPuy as they claim to not have been warned against the risks.

    • Tweet
     
     

    If you or a loved one has been injured, submit your claim for a free consultation here or call toll free 800.721.2519



    « Toward The Past: Carey Danis & Lowe Attorneys Investigate Lexapro Birth Defect Link
    Toward The Future: Yaz/Yasmin DVT & Pulmonary Embolism Settlements Progressing »



    This artice has been read 491 times.


    Filed under: Defective Medical Device litigation, Hip/Knee Replacement
    Tagged with: , ASR, defective, FDA, Federal Drug Administration, Johnson Johnson, metal on metal, recall
    Posted by: Scott Godar

     
    • Featured Cases & Current Litigation

      • Vaginal Mesh Litigation
      • Topamax® Birth Defects
      • Lexapro® & Birth Defects
      • Pradaxa® Internal Bleeding
      • Prozac® & Birth Defects
      • Yaz® & Yasmin® Blood Clots
      • Transvaginal Mesh Injury
      • Paxil® & Birth Defects
      • NuvaRing® Blood Clots
      • Mirena® IUD Complications
      • Asbestos Mesothelioma
      • Trucking Accidents & Passenger Vehicle Collision Settlements
    • Recent Posts & News Articles

      • NuvaRing Lawsuit News from Carey Danis & Lowe NuvaRing Law Firm: Seven Cases Removed from NuvaRing Multicounty Litigation in New Jersey
      • Carey Danis & Lowe Actos Lawyers Comment on Annulled Cooper v. Takeda Compensatory Award
      • Chicago DePuy Hip Trial Jury Rules in Favor of Johnson & Johnson and DePuy
      • Cooper v. Takeda Jury Presented with Plaintiff Closing Argument Linking Actos and Bladder Cancer
      • Bayer Loses Yaz Patent in Federal Court of Appeals: Generic Yaz Versions Begin (Stealing) Marketshare
      • Carey Danis & Lowe Pradaxa Lawyers Currently Following Pradaxa MDL 2385
      • FDA Approves New Anticoagulation Reversal Agent and Boehringer Ingelheim Updates Pradaxa Label
      • Carey Danis & Lowe Actos Cancer Lawyers Optimistic Following Cooper v. Takeda $6.5 Million Compensatory Award
    Our Offices
    Saint Louis, Missouri
    8235 Forsyth Ste 1100
    St. Louis, MO 63105
    T. 314 725 7700
    F. 314 721 0905
    Godfrey, Illinois
    5512 Godfrey Road
    Godfrey, IL 62035
    T. 618 463 0644
    F. 314 721 0905
    Belleville, Illinois
    5111 W. Main Street
    Belleville, IL 62226
    T. 618 212 6300
    F. 314 721 0905
    Vero Beach, Florida
    612 Beachland Blvd
    Vero Beach, FL 32963
    T. 314 725 7700
    F. 314 721 0905
    © 2013 Carey Danis & Lowe
    reVisioned.by
    Toll Free P. 800-721-2519
    Home • Contact • About